FDA Approves Zepbound: A New Weight Loss Drug Competing with Ozempic and Wegovy

The FDA has approved Zepbound, an obesity drug developed by Eli Lilly & Co., which will compete with Novo Nordisk's Wegovy. Zepbound has shown greater weight loss at a lower price compared to Wegovy and will be available in the U.S. by the end of the year. The drug works by targeting hormone receptors in the brain that regulate appetite and metabolism. Clinical trials have demonstrated an average weight loss of about 20% with Zepbound, and one in three users experienced a weight loss of about a quarter of their body weight. However, common side effects include nausea, diarrhea, constipation, and vomiting. The FDA highlighted the growing public health concern over excess weight and the need for new treatment options. The cost of Zepbound will depend on insurance coverage, but Lilly is offering discounts to help reduce the expense.